Bessemer Group
PACB icon

Bessemer Group’s Pacific Biosciences PACB Stock Holding History

Bessemer Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-184
Closed – – 2663
2025
Q2 		$0 Hold
184
– – ﹤0.01% 2582
2025
Q1 		$0 Sell
184
-571
-76% -$876 ﹤0.01% 2665
2024
Q4 		$1K Hold
755
– – ﹤0.01% 2381
2024
Q3 		$1K Buy
+755
New +$1.24K ﹤0.01% 2497

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Bessemer Group's PACB Position: Q3 2025 in Review

Bessemer Group sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 184 shares.

Bessemer Group first reported a position in PACB in Q3 2024 and held it in 4 quarters. The position peaked at $1K in Q4 2024. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • Bessemer Group reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 184 Pacific Biosciences shares in Q3 2025.
  • Bessemer Group first reported a position in Pacific Biosciences in Q3 2024 and held it in 4 quarters.
  • Bessemer Group's Pacific Biosciences position peaked at $1K in Q4 2024.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.